What question did this study set out to answer?

This study aims to assess the risks of venous thromboembolism (VTE) in pregnant women, particularly focusing on contributing factors such as thrombophilia.

January 1, 2001Thrombosis and Haemostasis

Thrombophilia, Thrombosis and Pregnancy

View Full Paper

Ask AI

Bookmark

Key result

This text is a journal masthead and editorial board listing, containing no clinical study data.

Why the study?

Do low-molecular-weight heparins prevent VTE and improve pregnancy outcomes in pregnant women with thrombophilia or previous VTE?

Population

Pregnant women, especially those with thrombophilia, previous VTE, or obstetric complications

Design

Review

Authors

AEAmiram EldorUniversité Claude Bernard Lyon 1

Discussion

Member takes

Implication

Journal masthead provides no data on LMWH in pregnancy; leaves open questions on VTE prevention and outcomes.

Key Points

This study aims to assess the risks of venous thromboembolism (VTE) in pregnant women, particularly focusing on contributing factors such as thrombophilia.
Analyzed the impact of maternal age, history of VTE, and thrombophilia on VTE risk in pregnancy.
Evaluated the effectiveness of low-molecular-weight heparins (LMWHs) compared to unfractionated heparin for VTE treatment during pregnancy.
VTE risk in pregnancy is 0.05-1.8%, significantly higher than non-pregnant women, with pulmonary embolism being a leading cause of maternal death.
Thrombophilia is present in nearly two-thirds of women with recurrent pregnancy complications, indicating a strong correlation with adverse outcomes.
LMWHs are found to improve pregnancy outcomes among women with previous obstetric complications.

Structured PICO

Do low-molecular-weight heparins prevent VTE and improve pregnancy outcomes in pregnant women with thrombophilia or previous VTE?

Population

Pregnant women, especially those with thrombophilia, previous VTE, or obstetric complications

Intervention

Low-molecular-weight heparins (LMWHs)

Outcome

Prevention and treatment of VTE during pregnancy

LMWHs are the preferred antithrombotic therapy for the prevention and treatment of VTE and improvement of obstetric outcomes in pregnant women with thrombophilia.

Cite This Study

Amiram Eldor (2001) studied this question. This text is a journal masthead and editorial board listing, containing no clinical study data.

synapsesocial.com/papers/6a0ed38e1c5e2d2319f9eeec https://doi.org/10.1055/s-0037-1616206

View Full Paper

Ask AI

Bookmark

Thrombophilia, Thrombosis and Pregnancy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Thrombophilia, Thrombosis and Pregnancy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider